The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
Publications
Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome.
Clinical medicine insights. Case reports 2018;11;1179547618770688 — 2018 — 1179547618770688
[Hydroxyurea-induced pneumonia].
Revue des maladies respiratoires 2014 May;31;430-4 — 2014 May — 430-4
[Acute interstitial pneumopathy with fever caused by hydroxyurea].
Presse medicale (Paris, France : 1983) 2000 Feb 12;29;242-5 — 2000 Feb 12 — 242-5
Acute alveolitis induced by hydroxyurea in a patient with myeloproliferative syndrome.
Annals of hematology 1993 Sep;67;133-4 — 1993 Sep — 133-4
Hydroxyurea-induced acute interstitial lung disease.
Southern medical journal 1994 Jul;87;767-9 — 1994 Jul — 767-9
Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia.
Cancer chemotherapy and pharmacology 1990;27;168-9 — 1990 — 168-9